Treatment for Advanced Esophageal Cancer with Metastasis to Distant Organs and/or Lymph Nodes

DOI Web Site 19 References
  • Sawada Ryoichi
    Gastrointestinal Oncology Division, National Cancer Center Hospital
  • Kato Ken
    Gastrointestinal Oncology Division, National Cancer Center Hospital

Bibliographic Information

Other Title
  • 他臓器転移・高度リンパ節転移を伴う進行食道癌への対応
  • タ ゾウキ テンイ ・ コウド リンパセツ テンイ オ トモナウ シンコウ ショクドウガン エ ノ タイオウ

Search this article

Abstract

Esophageal cancer is a disease common in men. The primary tumor is most frequently located in the middle thoracic esophagus. The histological type is predominantly squamous cell carcinoma, and smoking and alcohol consumption are considered risk factors. The prognostic factors associated with esophageal cancer are weight loss of more than 10%, dysphagia, tumor stage, age, lymphatic invasion, and TNM stage. In addition, performance status is considered a common prognostic factor for esophageal cancer. In cases of advanced cancer with metastasis to other organs and distant lymph nodes, a schedule of cisplatin (CDDP, 80 mg/m2) plus 5-fluorouracil (5-FU, 800 mg/m2) (FP) therapy, to be administered every 3 weeks, has been established as a standard treatment in Japan. Occasionally, radiation therapy is used for symptom relief. Until now, the efficacy of molecular targeted drugs has not been demonstrated. Registration for the “Phase I/II study of docetaxel, CDDP and 5-FU therapy in patients with unresectable or recurrent esophageal cancer (JCOG0807) ” has now ended, and the results are expected.

Journal

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top